MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Pfizer
- Study ID
- NCT05090566
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Elranatamab + Nirogacestat — DRUGBCMA-CD3 bispecific antibody + gamma secretase inhibitor
- Elranatamab + lenalidomide + dexamethasone — DRUGBCMA-CD3 bispecific antibody + immunomodulatory
Study Details
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Key Dates
- Start date
- Oct 27, 2021
- Status verified
- Apr 2026
- Primary completion
- Feb 13, 2025
- Completion
- Mar 11, 2026
Study Design
- Enrollment
- 46 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Sub-Study ABCMA-CD3 bispecific antibody + gamma secretase inhibitor
- Experimental: Sub-Study BBCMA-CD3 bispecific antibody + immunomodulatory drug
Primary Outcome Measure
SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation [ Time Frame: From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 35 days) ]
Locations (22)
Related coverage on Hipa.ai
- Elranatamab Multiple Myeloma Combination Trial Terminated, DLTs ReportedElranatamab · Feb 23, 2026 · ClinicalTrials.gov
Find similar trials in Gilbert, AZ
By condition
By specialty
Related Studies
- Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruiting · Boston Medical Center · Boston, Massachusetts
- Collection of Tissue Samples for Cancer ResearchRecruiting · National Cancer Institute (NCI) · Sacramento, California
- Tissue Collection for Studies of Lymph CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado